Aspire Biopharma Holdings (ASBP) Other financing activities (2022 - 2025)
Aspire Biopharma Holdings (ASBP) posted quarterly Other financing activities of -$1.0 for Q3 2025, down 100.0% quarter-over-quarter from $265828.0 in Q1 2025.
Aspire Biopharma Holdings (ASBP) Other financing activities (2022 - 2025) Analysis & Trends
Aspire Biopharma Holdings (ASBP) has reported Other financing activities for 2 consecutive years, with -$1.0 the latest figure, recorded in Q3 2025.
- In Q3 2025, Other financing activities changed N/A year-over-year to -$1.0; the TTM figure through Dec 2025 stood at $265827.0 (changed N/A YoY), while the FY2025 annual figure was $265827.0, down 84.47% from the prior year.
- Other financing activities slipped to -$1.0 in Q3 2025 per ASBP's latest filing, from $265828.0 in the prior quarter.
- Across five years, Other financing activities topped out at $14.6 million in Q1 2022 and bottomed at -$1.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Aspire Biopharma Holdings | 8.30 Mn | -3.86 Mn | -30,086.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -1.00 |
| Sep 30, 2025 | -1.00 |
| Mar 31, 2025 | 265,828.00 |
| Mar 31, 2025 | 265,828.00 |
| Mar 31, 2022 | 14.65 Mn |
| Mar 31, 2022 | 14.65 Mn |